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A B S T R A C T
Malformations of cortical development (MCD) have been increasingly recognized as an important cause of intractable
epilepsy. The aim of our study was to define epileptogenicity of MCDs by correlating MRI, EEG and semiology of epilep-
tic attacks, and to determine the effect of MCD on drug resistant epilepsy. We also intended to reveal the utility of inte-
rictal single photo emission computed tomography (SPECT) in verification of MCD lesions and relative prevalence of
different MCDs. Based on interictal EEG finding, semiology of the epileptic attacks and brain magnetic resonance imag-
ing (MRI) »electroclinical epileptogenicity« of MCD was defined. Brain MRI revealed cortical dysplasia (CD) in nine pa-
tients, polymicrogyria in four patients, lissencephaly and schizencephaly in one patient each. Three patients had a com-
bination of malformations. The localization of SPECT hypoperfusion corresponded to MCD lesion in ten (66.67%)
patients. Electroclinically confirmed epileptogenicity of MCD overlapped with MR and interictal SPECT findings in
fourteen (93.3%) and nine (60.0%) patients, respectively. Our study results demonstrated the MCD lesions to be highly
epileptogenic and a frequent cause of intractability.
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Introduction
Malformations of cortical development (MCD) repre-
sent heterogeneous group of disorders and a common
cause of epilepsy1,2. The high incidence of dysplastic neu-
rons in patients with drug resistent epilepsy has been in-
creasingly recognized since a detailed report by Taylor et
al. in 1971, who identified the disorientated or giant neu-
rons in temporal cortex resected from patients with tem-
poral lobe epilepsy3. High-resolution brain magnetic res-
onance imaging (MRI) can demonstrate these patholo-
gies in most ases morphologically if T1, T2, and fluid-at-
tenuated inversion recovery (FLAIR) images are investi-
gated carefully4,5.
There is a general consensus that MCDs can be highly
epileptogenic6,7. The intrinsic epileptogenicity of MCDs
has been reported by Palmini et al using intraoperative
electrocorticography1. Ictal or continuous epileptogenic
discharges were mostly recorded from electrodes overly-
ing dysplastic gyri. Several studies confirm epileptogeni-
city of MCDs8,9. Zilles et al reported an increased NMDA
receptor binding in the dysplastic cortex10. Immunocyto-
chemical studies examining the distribution of AMPA
reeptor proteins had shown predominant increase of
GluR2/3 subunits in dysplastic neurons as well as de-
creased GluR1 and increased GluR4 mRNA expression in
dysplastic neurons11–13. Expression of GABA-A receptor
beta-1, beta-2, alpha-1 and alpha-2 subunit mRNAs was
decreased in dysplastic neurons13. Furthermore, the cau-
sal relationship between MCD and genesis of seizures
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has been validated through the correlation of the extent
of surgical resection with favorable seizure outcome in
patients with chronic epilepsy14. It is well known that
high seizure frequency, prolonged duration of seizures
and episodes of epileptic status, which are commonly
present in MCD patients, can lead to early cognitive de-
cline. Moreover, a long period of poor seizure control pro-
duces disturbed psychosocial functioning and thus un-
satisfactory quality of life15. Therefore, early treatment
of intractable epileptic attacks in patients with MCD is
crucial. Combination of many noninvasive as well as in-
vasive diagnostic procedures may contribute to defini-
tion of MCDs as well as EZ16. Nuclear medicine imaging
techniques may help in noninvasive definition of epi-
leptogenic lesion and, therefore, in selecting appropriate
patients for surgery17. Single photo emission computed
tomography (SPECT) and positron emission tomography
(PET) are nowadays routinely used in preoperative eval-
uation of selected patients with epilepsy18.
The aim of our study was to define the epilepto-
genicity of MCD by correlating MRI, EEG and semiology
of epileptic attacks in epilepsy patients. We also assessed
the occurrence of medical intractability in patients with
epilepsy due to MCD. Furthermore, we intended to re-
veal utility of interictal single photo emission computed
tomography (SPECT) in verification of MCD lesions seen
on MRI and relative prevalence of different MCDs.
Patients and Methods
In this prospective study patients were selected among
1872 epilepsy patients examined during the year 2007 in
Croatian Referral Centre for Epilepsy, Zagreb University
Hospital Centre in Zagreb. The main inclusion criterion
was the finding of MCD lesion on brain MRI. MRI find-
ings were reviewed and classified according to the recent
classification of MCD lesions19. All patients were on
antiepileptic treatment for at least one year. Finally, thir-
teen female and two male patients were included in the
study. The mean age of onset of epileptic attacks was 13.0
 9.1 years, whereas mean duration of epilepsy before ad-
mittance to our Center was 13.4  6.7 years. The mean
age at admission to our University Department was 26.4
 8.8 years. Three patients had onset of epileptic attacks
after 21 years of age. Three patients had primary gener-
alized epileptic seizures. Of the remaining twelve pa-
tients, eleven patients had partial epileptic seizure with
secondary generalisation (complex partial seizures in
nine and simple partial epileptic seizures in three pa-
tients) with secondary generalization (Table 1).
Based on interictal EEG finding, semiology of the epi-
leptic attacks and brain MRI »electroclinical epilepto-
genicity« of MCD was defined. The »electroclinical epi-
leptic zone« (EZ) could not be precisely defined without
seizure registration by long term videoEEG monitoring
(ictal EEG) or special subdural grid electrodes7,20. The
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TABLE 1
SUMMARY OF THE CLINICAL DATA, MRI, SPECT AND EEG FINDINGS
Pt. Sex
Epilepsy onset /
age (yr)
MRI (type /
hemisphere / lobe)
Resistance
Semiology
of attacks
SPECT (perfusion /
hemisphere / lobe)
EEG
1. M 10 / 34 Schizencephaly / L / F R SPS HYPO– / L / F L / FP
2. F 15 / 22 CD / R / P S GM HYPO– / R / TP R / FTP
3. F 16 / 20 CD / L / T S CPS® HYPO– /R / T L / T
4. F 10 / 18 CD / R / T S CPS® HYPO– / R / T R / T
5. F 5 / 17
Polymicrogyria / R / TO +
heterotopia / R / TPO
R CPS® HYPO– / R / T R / T
6. F 24 / 33 Polymicrogyria / R / FT R CPS HYPO– / R / T R / T
7. M 5 / 18 CD / L / F R CPS® HYPO– / L / F L / T
8. F 38 / 45 CD / R / T R GM HYPO– / R / T R / FT
9. F 21 / 31 Polymicrogyria / L / T S CPS® HYPO– / R / T L / T
10. F 8 / 17 CD / L / T R CPS® HYPO– / L / T L / T
11. F 2 / 18
Lissencephaly / L / FP +
agenesis of corpus callosum
R SPS® ISO L / FP
12. F 10 / 27
Polymicrogyria / R / FT +
heterotopia / R / P
R GM HYPO– / R / FT R / FT
13. F 13 / 33 CD / L / FP S SPS® HYPO– / L / TP L / FP
14. F 8 / 26 CD / L / T R CPS® ISO L / T
15. F 10 / 37 CD / L / T R CPS® ISO L / T
Schi – schizencephaly, CD – cortical dysplasia, Po – polymicrogyria, H – heterotopia, Liss – lissencephaly, ACC – agenesis of corpus cal-
losum, ISO – isoperfusion, HYPO – hypoperfusion, F – frontal, T – temporal, O – occipital, P – parietal, L / R – left/right, EEG – elec-
troencephalogram, SPS – simple partial epileptic attacks; CPS – complex partial epileptic attacks, GM – generalized tonic-clonic sei-
zure. ® – partial seizure evolving to secondary GM
clinical details concerning patients’ resistance to medical
treatment, findings of MRI, interictal SPECT and »ele-
ctroclinical epileptogenicity« of MCD are summarized in
Table 1. Intractable epilepsy was defined as four or more
attacks per 4-week period during the last 12 weeks de-
spite two or more first-line antiepileptic drugs in therapy.
Patients with well-controlled seizures were free from at-
tacks in the same period. None of patients have under-
gone surgical treatment. An informed consent was ob-
tained from all patients.
MRI was performed on a TMR scanner with standard
techniques. T1-, T2-weighted and FLAIR images were
obtained in multiple coronal, sagittal and axial planes.
SPECT scans were performed interictally in all study pa-
tients and started 20 minutes after administration of 740
MBq of Tc-99m ECD in resting state, eyes closed and
with low ambient noise. Axial, coronal and sagittal im-
ages generated by IRIX triple headed gamma camera,
were analyzed on Odyssey FX820 work station semi-
quantitatively using the region-of interest based method
and normalized to the mean brain activity. Single slice
thickness was about 8 mm. Three-dimensional recon-
structions of the SPECT finding were obtained. Changes
of regional cerebral blood flow (rCBF) seen on interictal
SPECT were determined in comparison with rCBF in
morphologically normal regions, as assessed by MRI.
Finally, SPECT findings were divided in three major cat-
egories: scans with hypoperfusion area, hyperperfusion
area and normal scans. All patients underwent several
interictal scalp digital EEG recordings with interna-
tional 10/20 system of electrodes analyzed on Nihon
Kohden EEG-1100.
Results
According to neuroimaging findings, MCD lesions
were divided into several groups (Tables 1 and 2). Corti-
cal dysplasia (CD) was found in nine and polymicrogyria
in four patients, while lissencephaly and schizencephaly
were recorded in one patient each. Three patients had a
combination of malformations: patient 5 and 12 had focal
polymicrogyria accompanied by ipsilateral subcortical
nodular heterotopia (Figures 1, 2 and 3), whereas patient
11 had lissencephaly accompanied with partial agenesis
of corpus callosum. Megalencephaly/hemimegaencephaly
or MCD associated with neoplasia were not found. In
study patients, 73.3 % of lesions were unilobar, mostly lo-
cated in temporal or frontal lobes (Table 2).
According to our definition of intractability presented
in Patients and Methods section, ten patients had intrac-
table epileptic attacks. The remaining five patients had
well controlled epilepsy with no epileptic attacks over a
12- week period. Intractable epilepsy was found in five
CD (55.6%) patients, three (75%) patients with poly-
microgyria and one patient with schizencephaly and li-
ssencephaly each (Table 1).
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Fig. 1. Axial T2-weighted brain MRI image with nodular hetero-
topic gray matter in subcortical region and obliterated occipital
horn of right lateral ventricle. The right occipito-temporal lobe is
hypoplastic and shows changes typical for polymicrogyria. The
posterior interhemispheric fissure is discretely displaced to the
left (patinet no. 5).
Fig. 2. Axial interictal SPECT section with decreased regional
cerebral blood flow in the right temporal lobe cortico-subcortical-
ly (arrow) and evident hypoplasia of the right temporo-occipital
lobe (patient no. 5).
Fig. 3. Three-dimensional reconstruction of interictal SPECT
with a »hole« in the right temporal lobe, which represents decrea-
sed cerebral blood flow. Temporo-occipital hypoplasia is also
present (patient no. 5).
Hypoperfusion on interictal Tc-99m ECD SPECT was
found in 12 (80.0 %)patients without hyperperfusion.
SPECT findings in other three (20%)patients were unre-
markable (Table 1). Among various MCD subgroups,
hypoperfusion was revealed in seven of nine (77.8 %) pa-
tients with cortical dysplasia and in all patients with
polymicrogyria (Table 2).
The localization of hypoperfusion seen on interictal
SPECT matched with MCD lesions found by MRI in ten
(66.7 %) patients (Table 1). Three-dimensional recon-
struction of SPECT findings showed a significantly re-
stricted area of hypoperfusion in comparison to the ex-
tent of MRI finding. The localization of EEG changes,
interictal SPECT hypoperfusion and brain CT lesions
correlated with the MRI visible MCD lesion in fourteen,
ten and four patients, respectively. Finally, electroclini-
caly confirmed epileptogenicity of MCD overlapped with
MR and interictal SPECT findings in fourteen (93.3%)
and nine (60.0%) patients, respectively.
Discussion
MCDs are a group of developmental disorders of the
cerebral cortex, which can differ in clinical presentation,
imaging, genetic and pathologic findings. In forms that
are currently recognizable in vivo by high resolution
MRI, they are increasingly recognized as important cau-
ses of developmental delay, intractable epilepsy and other
neurological disorders19,21. The true incidence of MCD is
even higher, because even high resolution MRI fails to
detect some MCDs that are present on pathological in-
spection.
Recent classification of MCDs19 provides a useful and
logical scheme which can help clinicians in patient classi-
fication22. According to MRI findings, cortical dysplasia,
heterotopia, polymicrogyria and lissencephaly are among
the most common MCD types presented to the tertiary
hospital centers because of intractable epilepsy19,21,6,20,23.
In our study, nine patients were classified as cortical
dysplasia. Such a high number could be explained with
higher prevalence of intractable epilepsy in patients with
cortical dysplasias and hence more common findings on
MRI and in pathological specimens examined in tertiary
hospital centers22. The incidence of MCD in the group of
epilepsy patients examined during the last year at our
Center (N=1875 patients) was 0.8%. MCDs were present
in 4% of patients with intractable epilepsy (n=375, 20%)
examined in our Centre in 2007.
Because of higher morbidity and mortality rates, pa-
tients with intractable epilepsy represent major health
problem. The high frequency and prolonged duration of
seizures and episodes of epileptic status, which are com-
monly present in MCD patients, can cause early cogni-
tive decline as well as psychosocial disturbances result-
ing in inappropriate quality of life15. In our study group,
ten (66.7%) patients had intractable epileptic seizures
with inadequate quality of life. Additionally, epilepsy
caused by CD and lissencephaly is commonly refractory
to drug treatment; CD is an important cause of focal mo-
tor status and epilepsia partialis continua. However, po-
lymicrogyria is not invariably associated with epilepsy,
and it may present as developmental delay or congenital
hemiparesis22. However, in our study, only five (55.56%)
CD patients and even three (75%) patients with poly-
microgyria had intractable epileptic attacks. Therefore,
our results were not concordant with previous reports.
In our study, the localization of MCD lesion visible on
MRI matched with interictal EEG discharges in 93.3% of
patients, showing that clinical presentation of epileptic
attacks and EEG findings taken together highly indi-
cated to the localization of MCD lesion, thus suggesting
the high epileptogenicity of MCDs lesions. In contrast,
the localization of interictal SPECT changes confirmed
interictal EEG findings in only 60.0% of patients.
Based on the intrinsic epileptogenicity of MCD, sur-
gery became the most important modality of treatment.
Nowadays, preoperative evaluation is focused on the ac-
curate localization of EZ, rather than the MRI visible le-
sion alone, because some MCDs may well exceed abnor-
mality identified onMRI6,20,24. Therefore, patients under-
going resective epilepsy surgery for focal MCD may have
worse seizure outcome than those with epilepsy due to
other focal lesions 16. Conversely, the extent of MRI ab-
normalities may be more extensive than EZ. This was
oberved in patients with good postoperative outcome
where total resection of MCD lesion apparent on MRI
was not performed25–27. Because of this discordance be-
tween MRI detectable lesion and EZ, the addition of
other noninvasive as well as invasive techniques in pre-
operative evaluation is necessary. Functional methods
are important because they are complementary to struc-
tural images, which show only morphology of the lesion
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TABLE 2
MORPHOLOGICAL AND FUNCTIONAL CHARACTERISTICS OF MCD SUBGROUPS
MCD subgroups No. of patients Unilobar / multilobar Temporal / frontal lobe involvement SPECT hypoperfusion
Cortical dysplasia 9 8 / 1 6 / 2 7
Polymicrogyria 4* 3 / 2 2 / 1 4
Lissencephaly 1§ 0 / 1 1 / 2 0
Schizencephaly 1 1 / 0 0 / 1 1
Total 15 11 / 4 9 / 6 12
* In two patients (patient no. 5 and 12) with accompanying subcortical nodular heterotopia
whilw being unable to demonstrate changes in metabo-
lism and excitation in and around the MCD lesion. The-
refore, the addition of functional imaging techniques,
such as SPECT and PET has several benefits: it may con-
firm findings seen on MRI, and sometimes even lesions
invisible on MRI. SPECT has several advantages over
PET: it is relatively inexpensive to perform, widely avail-
able and more accessible. The utility of interictal SPECT
in detecting the EZ in patient with MCD had been dem-
onstrated in several studies28–30. Results showed hypo-
perfusion in 44 % to 62%, and hyperperfusion in 4% of
patients with cortical dysplasia28,29. These percentages
are surprisingly low, since focal cortical dysplasia lesions
have previously been described as highly and intrinsi-
cally epileptogenic lesions30. Our opinion is that the main
reason for the low percentage lies in the SPECT techniq.
Ictal SPECT is the best techniq to determine EZ, how-
ever we have ethical and financial problems related to
the issue. In our study, interictal SPECT hypoperfusion
was detected in seven (77.77%) of nine patients with fo-
cal cortical dysplasia without hyperperfusion. Additio-
nally, in a study that included a heterogeneous group of
MCD patients, interictal SPECT revealed hypoperfusion
in 62% and hyperperfusion in 17% of 24 patients31. The
latter study is comparable to ours according to MCD het-
erogeneity and percentage of hypoperfusion on interictal
SPECT.
The results of our study confirmed that MCDs are
highly epileptogenic and therefore a common cause of in-
tractable epilepsy. Our aim was not to define epilep-
togenic zone in MCD in preoperative evaluation, as it
would require ictal SPECT, ictal EEG with long term
monitoring and special cortical or other type of invasive
EEG monitoring. The MCD types predominant in our
study corresponded to MCD types reported in other
studes conducted at tertiary medical centers. Interictal
SPECT provides moderately useful information to local-
ize MCD in patients with apparent MRI lesion and in-
tractable epilepsy. However, in combination with clinical
presentation, MRI and EEG, it represents basic diagnos-
tic approach before using other ictal diagnostic tech-
niques. Nowadays, only a multimodality approach can
bring up good preoperative definition of EZ and postop-
rative outcome. Moreover, daily technological improveents
will in the future enable better preoperative detection of
EZ extent, which is the key for better postoperative out-
come.
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EPILEPSIJA UZROKOVANA MALFORMACIJAMA U KORTIKALNOM RAZVOJU
– KORELACIJA KLINI^KIH, MRI i Tc-99mECD SPECT NALAZA
S A @ E T A K
Malformacije kortikalnog razvoja (MKR) sve se vi{e raspoznaju kao va`an uzrok farmakorezistentne epilepsije. Cilj
studije bio je utvrditi epileptogenost MKR koreliraju}i MRI, EET i simptomatologiju epilepti~nih napada, te odrediti
povezanost MKR na farmakorezistentnost epilepsije. Tako|er je namjera bila utvrditi korisnost interiktalne pretrage
SPECT-a za potvrdu pro{irenosti MRK i relativnu u~estalost razli~itih tipova MKR. Simptomatologija epilepti~nih na-
pada i »elektroklini~ka epileptogenost« MKR prema nalazu MRI mozga utvr|ene su na osnovi interiktalnih nalaza
EEG. MRI mozga je otkrila kortikalnu displaziju u devetoro bolesnika, polimikrogiriju u ~etvoro bolesnika, te lisencefa-
liju i shizencefaliju u po jednog bolesnika, dok je troje bolesnika imalo kombinaciju razli~itih malformacija. Lokalizacija
hipoperfuzije na SPECT-u odgovarala je o{te}enju MKR u desetoro (66,67%) bolesnika. Elektroklini~ki potvr|ena epi-
leptogenost MKR preklapala se s nalazima MRI i interiktalnog SPECT u ~etrnaestoro (93,3%) odnosno devetoro
(60,0%) bolesnika. Na{i su nalazi pokazali kako su MKR visoko epileptogena i ~est razlog farmakorezistentnosti u
bolesnika sa epilepsijom.
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